• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India.

作者信息

Varshney Amit, Rawat Ramakant

机构信息

Kanti Devi Medical College Hospital and Research Center, Department of Emergency Medicine - Mathura (UP), India.

Uttar Pradesh University of Medical Sciences, Department of Medicine - Etawah (UP), India.

出版信息

Rev Assoc Med Bras (1992). 2023 Aug 14;69(8):e20230090. doi: 10.1590/1806-9282.20230090. eCollection 2023.

DOI:10.1590/1806-9282.20230090
PMID:37585983
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10427181/
Abstract
摘要

相似文献

1
Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India.达格列净与恩格列净在印度2型糖尿病患者中的安全性和疗效比较。
Rev Assoc Med Bras (1992). 2023 Aug 14;69(8):e20230090. doi: 10.1590/1806-9282.20230090. eCollection 2023.
2
Empagliflozin (Jardiance) for Type 2 Diabetes Mellitus.恩格列净（欧唐静）用于2型糖尿病
Am Fam Physician. 2016 Dec 15;94(12):1014-1015.
3
Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.恩格列净对比达格列净在二甲双胍、格列美脲和二肽基肽酶 4 抑制剂控制不佳的 2 型糖尿病患者中的应用：一项 52 周前瞻性观察研究。
Diabetes Res Clin Pract. 2019 May;151:65-73. doi: 10.1016/j.diabres.2019.04.008. Epub 2019 Apr 4.
4
Dapagliflozin-Associated Diabetic Ketoacidosis.达格列净相关的糖尿病酮症酸中毒
Am J Ther. 2018 Nov/Dec;25(6):e765-e766. doi: 10.1097/MJT.0000000000000770.
5
Empagliflozin-induced ketoacidosis in a patient presenting with new-onset type 2 diabetes mellitus due to indolent pancreatic cancer.恩格列净致新发 2 型糖尿病酮症酸中毒 1 例：源于惰性胰腺癌。
Endokrynol Pol. 2020;71(3):283-284. doi: 10.5603/EP.a2020.0012. Epub 2020 Mar 10.
6
Dapagliflozin: A Sodium Glucose Cotransporter 2 Inhibitor for the Treatment of Diabetes Mellitus.达格列净：一种用于治疗糖尿病的钠-葡萄糖协同转运蛋白2抑制剂。
J Pharm Pract. 2016 Apr;29(2):165-71. doi: 10.1177/0897190014566308. Epub 2015 Jan 21.
7
[Empagliflozin: an oral antidiabetic with documented positive effect on cardiac mortality].恩格列净：一种对心脏死亡率有确切积极作用的口服抗糖尿病药物
Praxis (Bern 1994). 2016 Mar 16;105(6):349-50. doi: 10.1024/1661-8157/a002288.
8
Absolute benefits of empagliflozin in type 2 diabetes: a game changer?恩格列净在2型糖尿病中的绝对获益：一个改变游戏规则的因素？
Postgrad Med J. 2017 Jul;93(1101):373-375. doi: 10.1136/postgradmedj-2016-134741. Epub 2017 Apr 22.
9
Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes.比较达格列净和恩格列净作为附加疗法对 2 型糖尿病患者低血糖药物的长期有效性和安全性的评估。
J Diabetes Res. 2022 May 23;2022:2420857. doi: 10.1155/2022/2420857. eCollection 2022.
10
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.恩格列净、2型糖尿病患者的心血管结局及死亡率
N Engl J Med. 2016 Mar 17;374(11):1093-4. doi: 10.1056/NEJMc1600827.

引用本文的文献

1
Assessment of Gliflozins prescribing pattern in a United Arab Emirates tertiary-level care hospital.阿拉伯联合酋长国一家三级护理医院中格列净类药物处方模式的评估。
Front Pharmacol. 2025 Apr 1;16:1529528. doi: 10.3389/fphar.2025.1529528. eCollection 2025.
2
Elevating Expectations: Vericiguat in Heart Failure with Reduced Ejection Fraction.提升期望：维立西呱用于射血分数降低的心力衰竭
J Pharm Bioallied Sci. 2024 Dec;16(Suppl 4):S4010-S4012. doi: 10.4103/jpbs.jpbs_1392_24. Epub 2024 Dec 27.

本文引用的文献

1
Comparison of Efficacy and Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors as Add-On Therapy in Patients With Type 2 Diabetes.2型糖尿病患者中钠-葡萄糖协同转运蛋白2抑制剂作为附加治疗的疗效和安全性比较
Cureus. 2021 Apr 3;13(4):e14268. doi: 10.7759/cureus.14268.
2
Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial.达格列净可降低 2 型糖尿病患者的动态中心血压和脉搏波速度：一项随机、双盲、安慰剂对照的临床试验。
J Hypertens. 2021 Apr 1;39(4):749-758. doi: 10.1097/HJH.0000000000002690.
3
Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease.用 SGLT2 抑制剂控制 24 小时血压以预防心血管疾病。
Prog Cardiovasc Dis. 2020 May-Jun;63(3):249-262. doi: 10.1016/j.pcad.2020.04.003. Epub 2020 Apr 8.
4
Use of Dapagliflozin in the Management of Type 2 Diabetes Mellitus: A Real-World Evidence Study in Indian Patients (FOREFRONT).达格列净在 2 型糖尿病管理中的应用：印度患者的真实世界证据研究（FOREFRONT）。
Diabetes Technol Ther. 2019 Aug;21(8):415-422. doi: 10.1089/dia.2019.0052.
5
SGLT2 Inhibitors for Type 2 Diabetes Mellitus Treatment.用于2型糖尿病治疗的钠-葡萄糖协同转运蛋白2抑制剂
Fed Pract. 2015 Oct;32(Suppl 11):8S-15S.
6
Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity.钠-葡萄糖协同转运蛋白 2 抑制剂在肥胖治疗中的新作用。
Drugs. 2019 Feb;79(3):219-230. doi: 10.1007/s40265-019-1057-0.
7
Long-Term Efficacy and Safety of Empagliflozin Monotherapy in Drug-Naïve Patients with Type 2 Diabetes in Indian Subgroup: Results from a 76-week Extension Trial of Phase III, Double-Blind, Randomized Study.恩格列净单药治疗初治2型糖尿病印度亚组患者的长期疗效和安全性：一项III期双盲随机研究76周延长期试验的结果
Indian J Endocrinol Metab. 2017 Mar-Apr;21(2):286-292. doi: 10.4103/ijem.IJEM_517_16.
8
Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus.恩格列净可降低2型糖尿病患者的体重及脂肪分布指标。
Diab Vasc Dis Res. 2016 Mar;13(2):119-26. doi: 10.1177/1479164115616901.
9
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.在基础胰岛素治疗血糖控制不佳的2型糖尿病患者中加用恩格列净的影响：一项78周随机、双盲、安慰剂对照试验
Diabetes Obes Metab. 2015 Oct;17(10):936-48. doi: 10.1111/dom.12503. Epub 2015 Jul 14.
10
Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂：基础与临床药理学综述
Diabetes Ther. 2014 Dec;5(2):355-66. doi: 10.1007/s13300-014-0089-4. Epub 2014 Nov 26.